Skip to main content
SleepCited

[Melatonin for children with insomnia].

Amalie Berring-Uldum, Nanette Marinette Monique Debes, Charlotte Reinhardt Pedersen, Helle Holst
Review Ugeskrift for laeger 2018 2 atıf
PubMed
<\/script>\n
`; }, get iframeSnippet() { const domain = 'sleepcited.com'; const params = 'pmid\u003D29761771'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Çalışma Türü
Review
Popülasyon
Children and adolescents (0-17 years)
Müdahale
[Melatonin for children with insomnia]. None
Karşılaştırıcı
None
Birincil Sonuç
Sleep latency in children
Etki Yönü
Mixed
Yanlılık Riski
Unclear

Abstract

Treatment for insomnia with melatonin (MT) in children and adolescents aged 0-17 years has doubled since 2011. The efficacy and safety profile for MT in children has not been determined. Recent clinical trials indicate, that MT only has a clinical effect on sleep latency, not on total sleep time. Furthermore, it has emerged, that proper sleep hygiene can cure the sleep problem in 50% of the children. Typically, the safety evaluation only entails an unclassified report of adverse events. Two long-term studies investigate and dispel the potential influence of MT on puberty.

Kısaca

It has emerged, that proper sleep hygiene can cure the sleep problem in 50% of the children and that MT only has a clinical effect on sleep latency, not on total sleep time.

Used In Evidence Reviews

Similar Papers